Details of the Drug
General Information of Drug (ID: DM9Y4FL)
Drug Name |
Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; 10409-15-1; N-methyl-N-1,2,3,4-tetrahydronaphthalen-1-ylamine; Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine; 64037-95-2; ACMC-20mk8d; AC1L2G4R; 1-Naphthalenamine,1,2,3,4-tetrahydro-N-methyl-, (1R)-; SCHEMBL61095; 1-Naphthalenamine, 1,2,3,4-tetrahydro-N-methyl-; AC1Q410F; AC1Q410E; CTK4A2694; DTXSID70275501; JQEUPNKUYMHYPW-UHFFFAOYSA-N; MolPort-001-794-098; HMS1783D04; AKOS017269129; AKOS000118469; ENAMINE-BB EN300-11723; MCULE-6929246555; MB03780; NCGC00338944-02
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 161.24 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||